Every medical facility or response team will have a manual resuscitator or ventilator nearby. Healthcare workers will maintain oxygenation by squeezing the bag manually until the patient stabilizes or get hooked up to an automatic respiratory device.
Ventilators are indispensable in the treating patients with coronavirus infections stage 3 to 5 and other respiratory complications. The rapid rate of infections, and the number of patients in serious conditions, has surpassed the number of available ventilators. The shortage of ventilators leaves overworked health workers being the ones to operate manual ventilators for long periods (Read about: critical supply shortages).
In South East Asia alone, the COVID-19 pandemic will lead to a shortage of ventilators on the order of millions of units (CDC Pandemic Response Plans). An increase in conventional ventilator production is very likely to fall short and with significant associated cost.
We believe that humanity will triumph over the COVID19 pandemic with minimized casualties when we harvest the best uses of technology and practice solidarity in sharing knowledge.
Ethovent is meant to be a quick and safe response during emergencies. The prioritisation of basic and important features enables it to be produced locally at a rate of 30 units per day, starting from the cost price of USD1000. It is produced at a fraction of the cost of automatic conventional resuscitators in a shorter period. To know more, please contact us.
In the coping with limited resources, health workers are the most valuable contributors in ensuring that patients are given proper care and treatment.
Automating ventilators appears to be the simplest strategy that satisfies the need for low-cost mechanical ventilation, with the ability to be rapidly manufactured in large quantities. Moreover this would free up health workers to discharge other duties to more patients.